- Home
- PYXS vs IMRX Comparison
PYXS vs IMRX Comparison
Compare PYXS & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYXS
- IMRX
- Stock Information
- Founded
- PYXS 2018
- IMRX 2008
- Country
- PYXS United States
- IMRX United States
- Employees
- PYXS N/A
- IMRX N/A
- Industry
- PYXS Biotechnology: Pharmaceutical Preparations
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- PYXS Health Care
- IMRX Health Care
- Exchange
- PYXS Nasdaq
- IMRX Nasdaq
- Market Cap
- PYXS 243.5M
- IMRX 232.9M
- IPO Year
- PYXS 2021
- IMRX 2021
- Fundamental
- Price
- PYXS $4.69
- IMRX $7.11
- Analyst Decision
- PYXS Strong Buy
- IMRX Strong Buy
- Analyst Count
- PYXS 4
- IMRX 5
- Target Price
- PYXS $6.67
- IMRX $17.20
- AVG Volume (30 Days)
- PYXS 737.4K
- IMRX 1.2M
- Earning Date
- PYXS 11-03-2025
- IMRX 11-12-2025
- Dividend Yield
- PYXS N/A
- IMRX N/A
- EPS Growth
- PYXS N/A
- IMRX N/A
- EPS
- PYXS N/A
- IMRX N/A
- Revenue
- PYXS $2,820,000.00
- IMRX N/A
- Revenue This Year
- PYXS N/A
- IMRX N/A
- Revenue Next Year
- PYXS N/A
- IMRX N/A
- P/E Ratio
- PYXS N/A
- IMRX N/A
- Revenue Growth
- PYXS N/A
- IMRX N/A
- 52 Week Low
- PYXS $0.83
- IMRX $1.10
- 52 Week High
- PYXS $4.86
- IMRX $10.08
- Technical
- Relative Strength Index (RSI)
- PYXS 68.39
- IMRX 59.94
- Support Level
- PYXS $4.23
- IMRX $6.00
- Resistance Level
- PYXS $4.64
- IMRX $7.57
- Average True Range (ATR)
- PYXS 0.40
- IMRX 0.63
- MACD
- PYXS 0.03
- IMRX 0.05
- Stochastic Oscillator
- PYXS 88.61
- IMRX 73.58
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.